Ribon Therapeutics

Edit info

Founded: 2015

Location: Cambridge, MA

Employee range: 11 - 50

Clinical stage: Clin1

Therapy area: Solid tumors

Drug types: ONC, DRM

Lead product: RBN-2397

Funding: $25M Jan 2023; $65M C Jul 2021; $65M B Jan 2019; $20m Oct 2017; $10M Mar 2016

Investors: Novartis Venture, JJDC, Celgene, Column Group, Deerfield Management, US Venture Partners, Osage University Partners, Takeda Ventures, Euclidean Capital, Pfizer

ribontx.com

linkedin.com

job board

Drug notes:

RBN-3143 Clin1 atopic dermatitis; 3 undisclosed programs RD undisclosed

About:

Ribon Therapeutics is a clinical-stage biopharmaceutical company developing novel small molecules targeting stress support pathways in cancer and inflammation. The company's lead product candidate, RBN-2397, is a potent, selective, and orally available small molecule inhibitor of the monoPARP, PARP7, for the treatment of solid tumors. Ribon Therapeutics is also developing RBN-3143, a PARP14 inhibitor, for the treatment of solid tumors and hematologic malignancies.

Jobs:

Main

Contact: recruit@workinbiotech.com